September 2, 2019
SIC Group Guangdong, Hong Kong, Macau and Bay Area Investigation Team Visited Quacell Biotechnology
On the morning of August 30, National Development Investment Group Co., Ltd. commissioned China Investment Consulting Co., Ltd. to conduct a research survey on the "Investment Opportunities of SDIC Group in Guangdong-Hong Kong-Macau Greater Bay Area." Dr. Yuan Jun and Wu Fan, Vice Presidents of Quacell, warmly received the investigating group.
Issued by the Central Committee of the Communist Party of China and the State Council, the Outline of the Development Plan for the Guangdong-Hong Kong-Macau Greater Bay Area states, "Support Zhongshan to promote biomedical technology innovation." This signifies that Guangdong-Hong Kong-Macau Greater Bay Area has entered a substantive development stage and points out that Zhongshan has taken the lead in biomedical technology innovation. The construction of Guangdong-Hong Kong-Macau Greater Bay Area will promote the Big Health industry's more significant development.
To capture investment opportunities, the research team planned to analyze the industrial development plan and enterprise development of Zhongshan under the planning of Guangdong-Hong Kong-Macau Greater Bay Area through on-site investigation. Quacell Biotechnology, as the most promising startup in Zhongshan Health Pharmaceutical upstream industry in Guangdong-Hong Kong-Macau Greater Bay Area, was the focus of this research.
In the Quacell Biotechnology R & D Hallway, Wu Fan introduced Quacell's business development, teams' performances and goal accomplishments, core technology platforms, and the future development plan to the investigating group. Later, Dr. Yuan Jun led the group to visit Quacell's R & D Laboratory, Quality Control Laboratory, GMP Production Workshop. The investigating group fully appreciated the excellent progress made by Quacell Biotechnology in the past 20 months and expressed great optimism about the superb momentum and development prospects of Quacell Biotechnology, hoping to strengthen communication in the future.
Congratulation!! | Quacell won the title of excellent enterprise in the 10th China Innovation and Entrepreneurship Competition (growth group)!
News | QuaCell Biotechnology announced that it had completed nearly 200 million yuan of round B financing
Dr. Poon, CEO of QuaCell Biotechnology, Co., Ltd. was honored to be elected Associate Editor of RE: GEN Open
Conclusion | Biofuture2021
BIG EVENETS. Day 2 | Biofuture 2021